产品说明书

Difluprednate

Print
Chemical Structure| 23674-86-4 同义名 : W-6309
CAS号 : 23674-86-4
货号 : A794471
分子式 : C27H34F2O7
纯度 : 98%
分子量 : 508.551
MDL号 : MFCD00214273
存储条件：

粉末 Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 250 mg/mL(491.59 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
描述 Difluprednate is a corticosteroid, approved difluprednate for the treatment of post-operative ocular inflammation and pain. Topical difluprednate is potentially effective and safe in preventing graft rejection after penetrating keratoplasty[3]. Difluprednate is effective for managing ocular manifestations of Harada's disease[4]. Difluprednate is also an effective treatment for patients with severe pseudophakic cystoid macular edema[5]. Difluprednate 0.05% four times daily showed safety and efficacy profiles similar to prednisolone acetate 1% four times daily in children 0-3 years undergoing cataract surgery[6]. Two months after initiation of topical difluprednate, fluorescein angiography demonstrated resolution of retinal vasculitis in both treated eyes[7].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT03626376 Herpes Simplex Virus Keratitis Phase 4 Not yet recruiting October 2019 United States, New York ... 展开 >> New York University School of Medicine Not yet recruiting New York, New York, United States, 10016 Contact: Stacy Mach    929-455-5539    Stacy.Mach@nyumc.org    Principal Investigator: Leela Raju, MD 收起 <<
NCT01541527 - Withdrawn(Promoter's change) - France ... 展开 >> CHU de Montpellier- Centre administratif André Benech Montpellier, France, 3400 收起 <<
NCT02215863 Influenza Str... 展开 >>eptococcus Pneumoniae 收起 << Phase 4 Completed - Korea, Republic of ... 展开 >> Korea University Ansan Hospital Ansan, Korea, Republic of Hallym University Gangnam Sacred Hospita Seoul, Korea, Republic of Catholic University Medical College, St. Vincent's Hospital Suwon, Korea, Republic of 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.97mL

0.39mL

0.20mL

9.83mL

1.97mL

0.98mL

19.66mL

3.93mL

1.97mL
参考文献

[1]Donnenfeld ED. Difluprednate for the prevention of ocular inflammation postsurgery: an update. Clin Ophthalmol. 2011;5:811-6.

[2]Jamal KN, Callanan DG. The role of difluprednate ophthalmic emulsion in clinical practice. Clin Ophthalmol. 2009;3:381-90.

[3]Said OM, Saleh MGA, Omar AF, Abdou AA, Riad Mostafa AN. Topical Difluprednate for Early Corneal Graft Rejection After Penetrating Keratoplasty. Clin Ophthalmol. 2020 Oct 27;14:3495-3498

[4]Onishi SM, Asahi MG, Chou C, Gallemore RP. Topical difluprednate for the treatment of Harada's disease. Clin Ophthalmol. 2015 Jan 21;9:157-67

[5]Chalam K, Khetpal V, Patel CJ. Spectral domain optical coherence tomography documented rapid resolution of pseudophakic cystoid macular edema with topical difluprednate. Clin Ophthalmol. 2012;6:155-8

[6]Wilson ME, O'Halloran H, VanderVeen D, Roarty J, Plager DA, Markwardt K, Gedif K, Lambert SR. Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study. Eye (Lond). 2016 Sep;30(9):1187-94

[7]Wang JC, Burkholder BM, Butler NJ. Topical difluprednate for the treatment of retinal vasculitis associated with birdshot chorioretinitis. Am J Ophthalmol Case Rep. 2016 Apr 29;3:22-24